Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: Aberrant p53 expression predicts response and survival

Leukemia and Lymphoma

Volumn 50, Issue 10, 2009, Pages 1559-1561

  Zenz, Thorsten ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLAVOPIRIDOL; FLUDARABINE; LENALIDOMIDE; PROTEIN P53; RITUXIMAB;

BONE MARROW BIOPSY; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; MUTANT; NOTE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION, MISSENSE; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 70350786596     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903159384     Document Type: Note

References (15)

1. Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007;12:303-312. (Pubitemid 47539312)
2. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
3. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem 2008;77:557-582.
4. Schlette EJ, Admirand J, Wierda W, et al. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 2009;50: 1597-1605.
5. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
6. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009;23:117-124.
7. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: Implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:995-1004.
8. Zenz T, Krober A, Scherer K, et al. Mono-allelic TP53 inactivation is associated with poor prognosis in CLL: Results from a detailed genetic characterization with long term followup. Blood 2008;112:3322-3329.
9. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
10. Zenz T, Smadova J, Vollmer D, et al. TP53 abnormalities in chronic lymphocytic leukemia exhibit a disease specific profile: Meta-analysis of 270 mutations. ASH Ann Meet Abstr 2008;112:2077.
11. Zenz T, Habe S, Denzel T, Winkler D, Dohner H, Stilgenbauer S. How little is too much? p53 inactivation: From laboratory cutoff to biological basis of chemotherapy resistance. Leukemia 2008;22:2257-2258.
12. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109:399-404.
13. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 2006;24:5343-5349.
14. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-5297.
15. Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory CLL: Dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009 Jul 30. [Epub ahead of print].